Insmed Presents New ARIKAYCE Data From Phase 3b ENCORE
Bridgewater, New Jersey, USA, September 3, 2026 Insmed Incorporated announced that five abstracts from its respiratory portfolio have been...
PAH
Advertisement
CalciMedica Advances Auxora and CM5480 in Pulmonary Hypertension
LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...
United Therapeutics Reports Phase 3 Ralinepag Results in The Lancet
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 29, 2026 United Therapeutics Corporation announced that the complete results...
Gossamer Bio Reacquires Global Rights to Seralutinib
San Diego, California, July 27, 2026 Gossamer Bio, Inc. announced a series of significant regulatory, strategic, and financial milestones...
Inhibikase Gains FDA Orphan Drug Status for IKT-001 in PAH
WILMINGTON, Del., July 23, 2026 Inhibikase Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Advertisements
CalciMedica Secures $49M Financing to Advance PH Program
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. (Nasdaq: CALC) announced a private placement financing of up to approximately...
Corsair Pharma Showcases Positive Phase 1 TRX-248 Data at PHA 2026
NEWARK, Calif., June 8, 2026 Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its...
Tiakis Advances Tiprelestat into Phase II for Pulmonary Hypertension
Kiel, Germany, December 2, 2025 — Tiakis Biotech has announced that it has successfully completed the required preclinical data...
Merck Reports Positive HYPERION Results for Pulmonary Hypertension Therapy
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
Advertisement
